Amprenavir

This classification denotes a protease inhibitor with the molecular formula C25H35N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S0W860XNR, chemically known as 4-amino-n-((2 syn,3s)-2-hydroxy-4-phenyl-3-((s)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-n-isobutyl-benzenesulfonamide but generally known as amprenavir, which bears US NIH Compound Identifier 65016. Amprenavir most often comes in base, phosphate, and phosphate calcium forms. European Medicines Agency schedules Amprenavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00511MIG. The term AMPRENAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 1, 1999, List 41). World Health Organization schedules amprenavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule amprenavir under HS 29350090 and SITC 51580. As of Q4 2014, AMPRENAVIR remains the US FDA Preferred Term for this commodity. Amprenavir bears US NLM identifiers UMLS ID C0754188 and NCI Concept Code C28824. SMILES: S(=O)(=O)(N(CC(O)C(NC(=O)OC1CCOC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1.